Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking

Study summary

RATIONALE: A stop-smoking plan that includes health education counseling and bupropion may help African-American smokers stop smoking. It is not yet known whether health education counseling is more effective with or without bupropion in helping African Americans stop smoking. PURPOSE: This clinical trial is studying health education counseling and bupropion to see how well they work compared with a placebo and health education counseling in helping African Americans smokers stop smoking.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedsmoking cessation intervention and bupropion hydrochloride

Plus 5 other study approaches.

Who it may be forBladder Cancer · Cervical Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Nov 13, 2017 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 4

Interventional

Where is it offered?2 U.S. locations

Locations may change over time.

Who runs it?Lisa Sanderson Cox, PhD

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 4
Sponsor: Lisa Sanderson Cox, PhD
Interventions being studied: Behavioral: smoking cessation intervention; Drug: bupropion hydrochloride; Genetic: gene expression analysis; Genetic: polymerase chain reaction; Other: counseling intervention; Other: educational intervention; Procedure: psychosocial assessment and care

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Supportive or behavioral care→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

DISEASE CHARACTERISTICS:
African American who has smoked ≤ 10 cigarettes per day for ≥ 2 years AND has smoked for ≥ 25 days within the past month
Not a heavy smoker
No other forms of tobacco within the past 30 days
Must be interested in stopping smoking
No other smoker in the household enrolled in this study PATIENT CHARACTERISTICS:
Has a home address and a functioning telephone number
Not planning to move from the Kansas City metro area within the next 12 months
Not pregnant or nursing
Negative pregnancy test
No alcohol or substance abuse within the past year
Not currently drinking ≥ 14 alcoholic drinks per week
No binge drinking (5 or more drinks on one occasion) on at least two occasions within the past month
No history of seizures or head trauma
No history of bulimia or anorexia nervosa
No myocardial infarction within the past 30 days
No reported use of opiates, cocaine, or stimulants
No diabetes requiring oral hypoglycemics or insulin PRIOR CONCURRENT THERAPY:
More than 30 days since prior nicotine replacement therapy, fluoxetine, clonidine, buspirone, or doxepin
No other concurrent medication that contains bupropion hydrochloride
No concurrent psychoactive medications

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Kansas Masonic Cancer Research Institute at the University of Kansas Medical CenterKansas City, Kansas
Swope Health CentralKansas City, Missouri

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 13, 2017. Always confirm current availability with the study team.

View original record ↗